Log in

Relevant bibliographies by topics / China. Lu jun. Di 2 jun

Contents

Journal articles
Books

Academic literature on the topic 'China. Lu jun. Di 2 jun'

Author: Grafiati

Published: 27 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'China. Lu jun. Di 2 jun.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "China. Lu jun. Di 2 jun"

1

He, Xue-Lian, Wen-Yan Huo, Li-Guang Zhang, et al. "Psilocybe ningshanensis (Hymenogastraceae, Agaricales), a new species from China." Phytotaxa 545, no. 2 (2022): 175–85. https://doi.org/10.11646/phytotaxa.545.2.6.

Full text

Abstract:

He, Xue-Lian, Huo, Wen-Yan, Zhang, Li-Guang, Liu, Yu, Qi, Peng, Dai, Lu, Qiao, Ting, Lu, Pengpeng, Li, Jun-Zhi (2022): Psilocybe ningshanensis (Hymenogastraceae, Agaricales), a new species from China. Phytotaxa 545 (2): 175-185, DOI: 10.11646/phytotaxa.545.2.6, URL: http://dx.doi.org/10.11646/phytotaxa.545.2.6

APA, Harvard, Vancouver, ISO, and other styles

2

Jin, Xiao-Feng, Yong-Di Liu, Yi-Fei Lu, Wen-Yan Sun, and Hong Wang. "Notes on Carex (Cyperaceae) from China (VI): the identity of Carex retrofracta Kük. (sect. Confertiflorae)." Phytotaxa 429, no. 2 (2020): 135–47. https://doi.org/10.11646/phytotaxa.429.2.4.

Full text

Abstract:

Jin, Xiao-Feng, Liu, Yong-Di, Lu, Yi-Fei, Sun, Wen-Yan, Wang, Hong (2019): Notes on Carex (Cyperaceae) from China (VI): the identity of Carex retrofracta Kük. (sect. Confertiflorae). Phytotaxa 429 (2): 135-147, DOI: 10.11646/phytotaxa.429.2.4, URL: http://dx.doi.org/10.11646/phytotaxa.429.2.4

APA, Harvard, Vancouver, ISO, and other styles

3

Zhao, Xinzhu. "Confucian Family Education and Ideological Tradition «Tian Di Jun Qin Shi»." RUDN Journal of Philosophy 25, no. 2 (2021): 311–19. http://dx.doi.org/10.22363/2313-2302-2021-25-2-311-319.

Full text

Abstract:

This article will briefly describe the features, methods, goals of family education in ancient China, as well as the relevant educational roles of the father and mother in the family. The article will also analyze one of the most unique characteristics of ancient Chinese family education: in each family fixed a tablet with the words 天地君亲 Tian Di Jun Qin Shi (Heaven, land, rulers, ancestors, sages). In ancient China, people believed that teachers and relatives, and heaven, earth, and monarchs, were objects that people should respect and worship. Obviously, this clearly differs from the traditio

APA, Harvard, Vancouver, ISO, and other styles

4

Wang, Mei-Hui. "Xiaolin: Un'esplorazione su barzellette e umorismo nella cultura cinese antica." Traduction et Langues 23, no. 2 (2024): 209–32. http://dx.doi.org/10.52919/translang.v23i2.1003.

Full text

Abstract:

Xiaolin: An Exploration of Jokes and Humor in Ancient Chinese Culture This article is based on the study of the book "Xiaolin" (The Forest of Laughter) by Handan Chun 邯鄲淳 (ca.132-ca.221) of the Cao Wei 曹魏 period in the Eastern Han Dynasty 東漢 (25-220).The first book dedicated to jokes in ancient China. The realistic and satirical folk stories produced against the backdrop of the times, reflected the interest in life, humor and the educational sense of the literati, lower-class and common peopleof that period (Wang, 1981; Huang, 1999). Focusing on the only 29 jokes left in the book, the extracts

APA, Harvard, Vancouver, ISO, and other styles

5

Zhang, Xianyu, Shiyao Lu, Hui Li, et al. "Abstract P1-05-27: Liquid Biopsy for HER2 Status Assessment in Breast Cancer Using Surrogate DNA Methylation Markers." Cancer Research 83, no. 5_Supplement (2023): P1–05–27—P1–05–27. http://dx.doi.org/10.1158/1538-7445.sabcs22-p1-05-27.

Full text

Abstract:

Abstract Background: Emerging HER2-targeted drugs especially antibody–drug conjugates (ADCs) are promising and provide more options for breast cancer management. Current assessment of HER2 status and treatment decisions are mainly dependent on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on the primary tumor tissues. With the disease progression, the molecular status of the tumor may evolve and become discordant with the primary site. However, longitudinal monitoring of HER2 status is limited by infeasible repeated sampling of the tumor tissues. A non-invasive and a

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Naifei, Chengfei Pu, Lingling Zhao, et al. "Abstract 1130: A phase 1 dose escalation study of GCC19CART - a novel CoupledCAR therapy for subjects with metastatic colorectal cancer." Cancer Research 83, no. 7_Supplement (2023): 1130. http://dx.doi.org/10.1158/1538-7445.am2023-1130.

Full text

Abstract:

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in hematologic malignancies but limited success in solid tumors. GCC19CART, the first clinical candidate from the CoupledCAR solid tumor platform, is designed to overcome the limitations of conventional CAR T-cells in solid tumor malignancies by pairing solid tumor CAR T-cells with CD19 targeting CAR T-cells to amplify proliferation and activation of the solid tumor CAR T component. GCC19CART targets guanylate cyclase-C (GCC) which is expressed in the metastatic lesions of 70%-80% of subj

APA, Harvard, Vancouver, ISO, and other styles

7

Shen, Hongling, Xiaofeng Xu, Hongfei Rong, et al. "Abstract 501: Discovery of BPI-460372, a potent and selective inhibitor of TEAD for the treatment of solid tumors harboring Hippo pathway aberrations." Cancer Research 83, no. 7_Supplement (2023): 501. http://dx.doi.org/10.1158/1538-7445.am2023-501.

Full text

Abstract:

Abstract The Hippo signaling pathway is critical for the regulation of organ development, tissue homeostasis, and tumorigenesis by controlling the activation status of yes-associated protein (YAP) or its homolog PDZ-binding motif (TAZ). As a major downstream effector, the transcription factor TEAD is activated by forming a complex with YAP/TAZ. Hippo pathway aberrations, such as NF2-deficiency or LATS1/2 mutations leading to hyperactivation of YAP/TAZ and subsequent activation of TEAD, have been reported in many cancers, including mesothelioma, meningioma, soft tissue sarcoma and non-small cel

APA, Harvard, Vancouver, ISO, and other styles

8

Mao, Lili, Jun Guo, Lingjun Zhu, et al. "Abstract CT519: FCN-159, a MEK1/2 inhibitor, in patients with advanced melanoma harboring NRAS mutations: A phase 1A dose-escalation study." Cancer Research 82, no. 12_Supplement (2022): CT519. http://dx.doi.org/10.1158/1538-7445.am2022-ct519.

Full text

Abstract:

Abstract Purpose: No targeted therapy has been approved for NRAS-mutant melanoma. We evaluated the safety and tolerability and determined the recommended phase 2 dose (RP2D) of FCN-159, a selective MEK1/2 inhibitor, in patients with NRAS-mutant advanced melanoma. Methods: This single-arm, open-label, dose-escalation, phase 1A study in China (NCT03932253) enrolled patients with unresectable stage III/IV melanoma harboring NRAS mutations. Patients received FCN-159 in doses escalating from 0.2 mg until the maximum tolerated dose (MTD). Oral FCN-159 was given once in the single-dose period and onc

APA, Harvard, Vancouver, ISO, and other styles

9

Liu, Yarong, Jingwei Sun, Yao Sheng, et al. "Abstract 4062: The discovery and development of a CRISPR/Cas9-engineered tumor-infiltrating lymphocytes product (GT316) as a next-generation TIL therapy." Cancer Research 83, no. 7_Supplement (2023): 4062. http://dx.doi.org/10.1158/1538-7445.am2023-4062.

Full text

Abstract:

Abstract Adoptive cell therapy by tumor-infiltrating lymphocytes (TILs) has demonstrated promising therapeutic effects in multiple types of solid tumors and significantly prolonged the survival of late-stage patients. However, the “prone-to-exhaustion” phenotype of the final TIL product after rapid expansion during manufacture and the presence of various immunosuppressive mechanisms in tumor microenvironment (TME) compromises the persistence and anti-tumor efficacy of TIL post infusion. To discover potential immunoregulatory targets that could maximize the function of TIL, we established a gen

APA, Harvard, Vancouver, ISO, and other styles

10

Frentzas, Sophia, Haesong Park, George Budd, et al. "Abstract PO1-04-01: Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients." Cancer Research 84, no. 9_Supplement (2024): PO1–04–01—PO1–04–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-04-01.

Full text

Abstract:

Abstract Introduction: ARX788 is a next-generation anti-HER2 antibody-drug conjugate (ADC) conjugated to amberstatin269 (AS269), a potent cytotoxic tubulin inhibitor. ARX788 is highly stable with nearly identical PK profiles for the total ADC and the total antibody due to proprietary site-specific oxime conjugation chemistry. The stability of ARX788 results in limited systemic toxicity and increased targeted delivery of payload to tumor cells. Clinical benefit of ARX788 has been observed in patients (pts) with HER2-positive (HER2-pos) breast cancer (BC) in multiple clinical trials and recently

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "China. Lu jun. Di 2 jun"

1

Fu, Jin, ed. Zhongguo xiong shi: Di er ye zhan jun : ming jiang pu, xiong shi lu, zheng zhan ji : Er ye dang an. 3rd ed. Zhong gong dang shi chu ban she, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

di 50. Jun shi bian xie zu China. Lu jun. Zhongguo ren min jie fang jun lu jun di wu shi jun jun shi, 1949-1985. s.n.], 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

China (Republic : 1949- ). Guo fang bu. Jun wu ju. Shi zheng chu., ed. Guo min ge ming jun lu jun di shi ba jun jun shi. Guo fang bu jun wu ju shi zheng chu, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bing, Meng, and Wang Yuanping, eds. Ba lu jun. Zhong yang wen xian chu ban she, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Baoxun, Dong, ed. Ba lu jun shi: Balujunshi. Qingdao chu ban she, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shaojun, Wang, ed. Ba lu jun zong bu. Jie fang jun chu ban she, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Yang, Maolin. Ba lu jun zai Shanxi. San Jin chu ban she, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Zhelong. Kang Ri de di ba lu jun. Beijing zhong xian tuo fang ke ji fa zhan you xian gong si, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Junfeng. Wo shi ba lu jun. Hunan ren min chu ban she, 2017.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

"Zhongguo kang Ri zhan zheng jun shi shi liao cong shu" bian shen wei yuan hui. Ba lu jun, tu pian. Jie fang jun chu ban she, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!